ArticleJournal of endocrinological investigation2026
Skeletal muscle expression of the genes associated with glycoprotein 130 signaling in relation to obesity and insulin sensitivity.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlycoprotein 130 (gp130) is a critical signal transducer in the interleukin-6 (IL-6) receptor family, regulates immune response, inflammation, and metabolic processes. In obesity, elevated levels of proinflammatory cytokines like IL-6 can lead to chronic activation of gp130, disrupting normal signaling in tissues such as skeletal muscle. The aim of the study was to investigate the expression of IL-6–related and JAK/STAT pathway genes in human skeletal muscle and to explore their association with insulin sensitivity, as well as to evaluate the role of serum soluble gp130 (sgp130) in the development of overweight and obesity.
methodsThe study included 57 participants, 25 with normal body weight (control group), 17 with overweight and 15 with obesity. Hyperinsulinemic-euglycemic clamp and muscle biopsy were conducted. Muscle mRNA expression was analysed by qPCR.
resultsIndividuals with overweight exhibited significantly lower IL6R expression in skeletal muscle, while those with obesity showed reduced IL6ST expression. The expression levels of IL6R (r = 0.28, p = 0.036), IL6ST (r = 0.46, p < 0.001), JAK2 (r = 0.32, p = 0.015), and STAT3 (r = 0.44, p < 0.001) and PRKAA2 (r = 0.26, p = 0.049) in skeletal muscle were positively correlated with insulin sensitivity. Additionally, individuals with overweight and obesity had significantly higher serum sgp130 levels. Serum sgp130 was positively correlated with BMI (r = 0.43, P < 0.01) and inversely associated with insulin sensitivity (r = -0.44, P < 0.01).
conclusionGp130 is associated with insulin sensitivity in skeletal muscle in obesity, revealing a novel mechanism linking gp130 to metabolic regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.